Cobus Loots, CEO of Pan African Resources, on delivering sector-leading returns for shareholders. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAMP.L Regulatory News (AMP)

  • There is currently no data for AMP

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

DSC Fundraising

27 May 2008 07:00

RNS Number : 2014V
Amphion Innovations PLC
27 May 2008
 

Amphion Innovations plc  Partner Company Durham Scientific Crystals, Ltd.  Closes £1.6 million Fundraising

London and New York, 27 May 2008 - Amphion Innovations plc (LSE: AMP) ("Amphion") the developer of medical and technology businesses, today announces that its Partner Company, Durham Scientific Crystals, Ltd. ("DSC") has successfully raised £1.6 million at £8 per share in a Series J financing.DSC, a Durham University spin-out, is pioneering digital colour imaging using x-rays. The Company is applying  ground breaking innovation in materials technology and advanced 3D imaging, radically changing the way x-ray imaging is currently done,  

Amphion now owns approximately 21% of the issued voting share capital on a fully diluted basis.  At £8 per share, DSC is currently valued at £46.5 million following this financing.

The principle use of these funds will be used to enable the continuation of the research and development programme, market research, the commercialisation of products spun-out of research and development, and the initial sales of products in the industrial and security sectors. DSC has signed a contract with the UK Home Office to develop a liquid and small object scanner and airport checkpoint baggage scanners and is progressing similar commercial opportunities in this sector and other areas where the Company's technology can be widely applied.

Richard C.E. Morgan, CEO of Amphion Innovations said, "Despite a more challenging fundraising environment, we have successfully raised an additional £1.6 million at double the valuation of the previous financing. This is a testament to the strength of DSC's innovative technology and we look forward to further positive developments in the future."

Dr. Arnab Basu, Chief Executive Officer of Durham Scientific Crystals said, "The Company is making great progress on both technical and commercial fronts and the support from our investors in this financing round is again a testament to our ability to reach targets and achieve goals."

DSC produces radically improved and more cost effective semiconductor materials than are currently available, which are used in detectors for medical, security, and defense digital x-ray imaging. The Company has commercialised the use of materials based on cadmium telluride, the premier choice for use as digital detectors of x-rays and gamma rays, and will allow for significantly improved imaging in markets such as airport security and medical imaging. In addition to its range of semiconductor materials, detector packages, and non imaging detection systems, DSC also supplies x-ray imaging packages with multi-view capabilities. These x-ray display platforms provide real 3D x-ray imaging for the first time, without specialist viewing equipment.

Cadmium telluride materials are currently too expensive and too difficult to produce to be used in large scale commercial applications. DSC, however, has developed a breakthrough production method to produce these crystals from a vapour phase, rather than the conventional liquid based techniques, enabling the crystals to be produced at an attractive cost and quality enabling their large scale commercial use in the future. The Company is currently developing detectors and its novel imaging system platform based on its fundamental competence of producing high grade cadmium telluride material and its novel 3D XRA™ imaging platforms.

For further information please contact

Amphion Innovations plc  Charlotte Morgan, Communications +1 212 210 6224

Cardew Group Tim Robertson/ Jamie Milton/ Matthew Law +44 020 7930 0777 (London)

Charles Stanley Securities - Nominated AdviserMark Taylor / Freddy Crossley +44 20 7149 6000

Durham Scientific Crystals, Ltd.  Arnab Basu, CEO +44 1740 625 255

About Amphion Innovations plc

Amphion (LSE: AMP) builds shareholder value in high growth companies in the medical and technology sectors, by using a focused, hands-on company building approach, based on decades of experience in both the US and UK. Amphion has significant shareholding in 10 Partner Companies developing proven technologies targeting substantial commercial marketplaces, each in excess of $1 billion. Each Partner Company is chosen with the goal of achieving an exit valuation in excess of $100 million.

On the web: www.amphionplc.com

About Durham Scientific Crystals, Ltd.

Durham Scientific Crystals, Ltd. ("DSC") is a research and development company, which was spun-out from the Physics Department of the University of Durham. The company, based in Sedgefield, County Durham, was formed in April 2003 and has been actively involved in the research and development of semiconductor materials and its unique 3D imaging modality. The company has a world leading capability in manufacturing the cadmium telluride family of semiconductor materials via its patented production process. These materials are used in high performance detectors of x-rays and gamma rays in multiple international markets, including medical imaging, security screening, and industrial inspection. DSC's detectors will enable fast digital imaging, using lower radiation dosage, together with precise materials identification.

In addition to the range of semiconductor materials and non-imaging products, DSC also offers XRA™ imaging packages with True Multi View™ capability and software for material detection. The XRA™ provides real 3D imaging with positional mapping facility for in-line processes at high speed.

On the web: www.dscrystals.com

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCILFLSEIIVFIT
Date   Source Headline
22nd Dec 20177:01 amRNSComment on Polarean Fund Raise
22nd Dec 20177:00 amRNSRestructure of Loan and Additional Drawdown
5th Dec 20177:00 amRNSIssue of Shares
23rd Nov 20177:00 amRNSFurther Update on Polarean Imaging Limited
10th Nov 20177:00 amRNSUpdate on Polarean Imaging Limited
2nd Nov 20177:00 amRNSOrder Dismissing DataTern Case
11th Oct 20177:00 amRNSRelated Party Transaction
5th Oct 20177:00 amRNSPartner Company releases positive clinical results
29th Sep 20177:00 amRNSHalf-year Report
25th Sep 20177:01 amRNSHolding(s) in Company
25th Sep 20177:00 amRNSSale of Partner Company Shares
30th Aug 20177:00 amRNSSale of partner company shares
30th Aug 20177:00 amRNSHolding(s) in Company
1st Aug 20175:19 pmRNSAGM Statement
28th Jun 20177:00 amRNSFinal Results
31st May 20177:00 amRNSPartner Company m2m Imaging merger update
22nd May 20174:36 pmRNSAdditional Draw Down on Loan Facility
7th Feb 20177:00 amRNSAdditional Draw Down on Loan Facility
1st Feb 20175:18 pmRNSHolding(s) in Company
30th Dec 20162:38 pmRNSHolding(s) in Company
16th Dec 20163:07 pmRNSDirector/PDMR Shareholding
9th Dec 20163:50 pmRNSDirector/PDMR Shareholding
24th Nov 20162:15 pmRNSHolding(s) in Company
8th Sep 20167:00 amRNSRe-negotiated terms of Motif CPN
7th Sep 20167:00 amRNSInterim Results for the six months to 30 June 2016
22nd Aug 20163:58 pmRNSAdditional Draw Down on Loan Facility
3rd Aug 20164:13 pmRNSHolding(s) in Company
29th Jul 20167:00 amRNSResults of AGM and Directorate Change
18th Jul 20164:33 pmRNSTransfer of Shares
13th Jul 20167:01 amRNSNotice of Intention to List on NASDAQ by Motif Bio
13th Jul 20167:00 amRNSAdditional Draw Down on Loan Facility
23rd Jun 20167:00 amRNSFinal Results
29th Apr 20164:02 pmRNSAdditional Terms on Loan Facility
28th Apr 20167:00 amRNSAdditional Draw Down on Loan Facility
7th Apr 20167:00 amRNSAmphion settles contested arbitration ruling
3rd Mar 20167:00 amRNSConvertible Promissory Note Extended
7th Jan 20167:00 amRNSDirectors' Dealings
5th Jan 20167:00 amRNSConvertible Promissory Note Terms Extended
26th Nov 20157:00 amRNSAdditional Draw on Loan Facility
5th Nov 20157:00 amRNSPartner Company m2m Imaging Corp. to merge
30th Oct 20154:20 pmRNSDeath of a Director - Replacement
30th Oct 20153:50 pmRNSDeath of a Director
17th Sep 20157:00 amRNSAmphion to present in London
16th Sep 20157:00 amRNSDirectors' Dealings
10th Sep 20157:00 amRNSDataTern Receives Favourable Ruling
3rd Sep 20157:00 amRNSInterim Results
28th Aug 20159:08 amRNSHolding(s) in Company
7th Aug 20155:15 pmRNSResult of AGM
22nd Jul 20154:32 pmRNSFDA QIDP Designation
22nd Jul 20157:00 amRNSFinal condition of £22m placing satisfied

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.